Can This Protein Make Cancer Treatment More Effective?
"New research highlights the potential of ZEB1 as a key player in DNA repair, offering new avenues for improving chemoresistance in colorectal cancer."
Chemo- and radio-resistance pose significant challenges in cancer treatment, often leading to recurrence and poorer outcomes. Researchers are constantly seeking ways to improve the effectiveness of these therapies and overcome resistance.
Recent studies suggest a connection between metastasis, cancer stem cells, and resistance to treatments. Epithelial-to-mesenchymal transition (EMT), where cancer cells gain migratory and invasive properties, plays a role in this resistance. Zinc finger E-box binding homeobox 1 (ZEB1) is a protein known to contribute to EMT and stemness, but its role in chemo- and radio-resistance is still being explored.
New research sheds light on how ZEB1 affects DNA repair processes in colorectal cancer cells. By understanding ZEB1's function, scientists hope to develop strategies that make cancer cells more vulnerable to treatment.
DNA Repair as a Therapeutic Target
Cancer research increasingly examines DNA damage and repair mechanisms as therapeutic targets, while traditional approaches such as surgery, chemotherapy, and radiotherapy continue to face important challenges. Reviews of DNA repair defects describe how impaired repair can produce genomic instability and create therapeutic vulnerabilities. Other work emphasizes the need to understand crosstalk among DNA repair and DNA damage response proteins and pathways. DNA repair pathways are also being developed as biomarkers for precision medicine-based cancer treatment.
ZEB1's Role in DNA Repair: A New Target for Cancer Treatment?
The study investigated how ZEB1 interacts with DNA damage response (DDR), the mechanisms cells use to repair damaged DNA. It was already known that ZEB1 affects the deubiquitylating activity of ubiquitin-specific peptidase (USP)7, which is important for DNA repair. Researchers hypothesized that ZEB1, as a transcriptional suppressor, might influence DDR by affecting other key components involved in DNA repair.
- ZEB1 Targets DDR Genes: ZEB1 directly interacts with the genes USP17, CHD1L, and DUX4, all involved in DNA damage response.
- E-boxes and ZEB1 Binding: Specific DNA sequences (E-boxes) within these genes confirm ZEB1's role as a transcriptional repressor.
- Knocking Down ZEB1 Increases Gene Expression: When ZEB1 was reduced, the expression of USP17, CHD1L, and DUX4 increased, indicating ZEB1 normally suppresses these genes.
- Increased Sensitivity to Chemotherapy: Reducing ZEB1 made cancer cells more sensitive to chemotherapy drugs, leading to cell cycle arrest and increased apoptosis (cell death).
ZEB1, USP17, and Treatment Resistance
Recent reviews connect ubiquitin-specific proteases and epithelial-mesenchymal transition with cancer drug resistance. One review reports that overexpression of USP17, described as a potential downstream target of ZEB1, makes cancer cells more susceptible to cisplatin-induced DNA damage. Another review reports that inhibiting ZEB1 can make colorectal cancer cells more susceptible to chemotherapy. Separate research identifies ZEB1 as a zinc-finger-family transcription factor and links USP17-regulated processes to the DNA-damage response in non-small cell lung cancer.
Early Evidence and Experimental Limits
Evidence for ZEB1 as a treatment-related target remains dependent on experimental models and mechanistic validation. In one colorectal cancer study, cisplatin and etoposide induced early apoptosis in 0.53% and 0.48% of scrambled control cells, compared with 1.02% and 0.69% of ZEB1-KD-1 cells and 1.99% and 3.13% of ZEB1-KD-2 cells. A separate report stated that predicted ZEB1-binding motifs still required confirmation by pull-down assay using recombinant ZEB1 protein and oligonucleotides. These findings support further investigation but do not by themselves establish clinical effectiveness.
Repair Pathways and Alternative Strategies
DNA repair proteins are essential for cell survival and execute repair through pathways such as homologous recombination. A 2025 review describes alternative repair proteins that evolution kept dormant within the genome and that may be activated when needed. Mitochondrial DNA is also vulnerable to damage in solid tumors and hematological malignancies, while compromised repair capacity can correspond with a more aggressive phenotype. DNA-targeting drugs may therefore be applied in the context of cancer-specific repair failure, with repair-pathway modulation proposed as a way to increase their efficacy.
The Future of Cancer Treatment: Targeting ZEB1
This research provides a foundation for understanding how ZEB1 regulates DDR and contributes to chemoresistance. It suggests that inhibiting ZEB1 could be a promising strategy for improving cancer treatment.
From Mechanisms to Patient Outcomes
The study of DNA repair in cancer spans genome stability, tumorigenesis, and therapeutic development. An editorial covering eleven review articles highlights current and future options focused on DNA damage and repair, as well as methods for studying crosstalk among DNA repair and DNA damage response proteins and pathways. The IMPACT2 study evaluated patients with advanced metastatic cancer across tumor types after tumor biopsy and molecular profiling in a CLIA-certified laboratory. Its analysis compared outcomes by treatment type, including anti-DNA damage repair agents, immunotherapy, and other treatments.
Combination Therapies Under Investigation
Current research is examining small-molecule inhibitors that target DNA repair mechanisms in cancer. A 2025 review reports that these inhibitors can clarify mechanisms of tumor resistance. That information may support the rational design of combination therapies intended to enhance treatment efficacy. The review focuses on DNA repair-targeted therapeutics that are currently under clinical investigation.
DNA Repair and Immunotherapy
DNA damage response and repair pathways have a broad role in cancer biology and therapy, spanning basic, translational, and clinical research. A 2026 Nature review examines how defects in these pathways shape tumor immunogenicity and influence responses to immune checkpoint inhibitors. The review also highlights shared relationships between DNA damage response defects and cancer immunotherapy. These connections place DNA repair research within a wider treatment system rather than a single-drug strategy.
Treatment Outcomes in Advanced Cancer
A 2026 study investigated treatment outcomes in patients with advanced cancer who did or did not have DNA repair pathway alterations. The study examined patients treated with immunotherapy, immunotherapy combined with non-immunotherapy treatment, and other treatment approaches. According to the report, it was the first study to investigate these outcomes in this patient context. Its focus illustrates how DNA repair findings are being evaluated through real-world clinical treatment outcomes.
By targeting ZEB1, researchers aim to simultaneously disrupt EMT, reduce stemness, and overcome drug resistance—three critical factors in cancer progression.
Further studies are needed to fully elucidate the detailed functions of USP17, CHD1L, and DUX4 in DDR and to develop effective ZEB1 inhibitors. However, this research offers a new avenue for developing more effective and targeted cancer therapies.